Crossmark

The Arf6 activator Efa6/PSD3 confers regional specificity and modulates ethanol consumption in Drosophila and humans

Crossref DOI link: https://doi.org/10.1038/mp.2017.112

Published Online: 2017-06-13

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Gonzalez, D A

Jia, T

Pinzón, J H

Acevedo, S F

Ojelade, S A

Xu, B

Tay, N

Desrivières, S

Hernandez, J L

Banaschewski, T

Büchel, C

Bokde, A L W

Conrod, P J

Flor, H

Frouin, V

Gallinat, J

Garavan, H

Gowland, P A

Heinz, A

Ittermann, B

Lathrop, M

Martinot, J-L

Paus, T

Smolka, M N

Rodan, A R

Schumann, G

Rothenfluh, A
License Information

Text and Data Mining valid from 2017-06-13
More Information

Article History

Received: 18 May 2016

Revised: 21 March 2017

Accepted: 11 April 2017

First Online: 13 June 2017

Competing interests

: TB served in an advisory or consultancy role for Hexal Pharma, Lilly, Medice, Novartis, Otsuka, Oxford Outcomes, PCM Scientific, Shire and Viforpharma. TB received conference attendance support and conference support or speaker’s fees from Lilly, Medice, Novartis and Shire. TB is/has been involved in clinical trials conducted by Shire and Viforpharma. JG has received research funding from AstraZeneca, Eli Lilly & Co., Janssen-Cilag and Bristol-Myers Squibb, and speaker’s fees from AstraZeneca, Janssen-Cilag and Bristol-Myers Squibb. The remaining authors declare no conflict of interest.